AbbVie announces positive phase 3 CERVINO trial results
Etentamig significantly improved response rates and progression-free survival in triple-class exposed relapsed/refractory multiple myeloma patients versus standard therapies.
See the latest news and media coverage for AbbVie. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company
abbvie.comLast updated
In short: AbbVie completed a $10.9 billion acquisition of Apogee Therapeutics and reported a 10.2 percent revenue increase for the second quarter.
Etentamig significantly improved response rates and progression-free survival in triple-class exposed relapsed/refractory multiple myeloma patients versus standard therapies.
The deal expands AbbVie's immunology pipeline with late-stage inflammatory disease therapies while maintaining existing full-year earnings guidance.
Net revenues rose 10.2% to $16.99 billion, with GAAP diluted EPS of $2.03 and adjusted diluted EPS of $3.65
The approval makes RINVOQ the first systemic treatment for non-segmental vitiligo in the EU, based on Phase 3 data.
AbbVie Inc. ABBV shares are edging higher Friday morning following Thursday's announcement of positive Phase 3 trial results for its menstrual migraine treatment, atogepant. Here's...
AbbVie beats Q1 expectations: adjusted earnings per share of $2.46 and revenue of $13.3 billion, exceeding forecasts by $550 million. Full-year earnings per share guidance raised to $12.09-$12.29...
AbbVie Announces Positive Phase 3 Atogepant Results in Menstrual Migraine CI 09:54am AbbVie's Menstrual Migraine Treatment Meets Primary, Secondary Endpoints in Phase 3 Trial DJ...
AbbVie said on Thursday its migraine treatment had in a late-stage study reduced the migraine days ...
Track AbbVie and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to AbbVie and other trending companies.